. 2023 May 19;19(8):539–546. doi: 10.1200/OP.22.00480

TABLE 2.

Recommended Guidance for Toxicity Management of T-DXd–Induced Pneumonitis/ILD From the DESTINY-Breast03 and DESTINY-Breast04 Protocols^7,9